Abstract
Introduction
Over 1.5 million Americans are diagnosed with a stroke each year, and excessive flexion or extension (hypertonia) of upper extremity joints are common secondary conditions. The purpose of this study was to compare the efficacy of botulinum toxin type-A and manual therapy, with the adjunct treatment of dynamic splinting on range of motion, spasticity, and elbow flexor hypertonia, in a randomized trial.
Methods
Thirty-six subjects were recruited for this pilot study and all exhibited hypertonia in elbow flexion. Six patients were excluded due to noncompliance. Testing was done with pre/post active range of motion in elbow extension, and the Modified Ashworth Scale (extension) for spasticity. All patients received the current standard of care: botulinum toxin type-A injections and manual therapy. Experimental patients were randomly assigned adjunct treatment with Elbow Extension Dynasplint®.
Results
Thirty patients completed the study (mean age [SD] 52±17 years). The percentage of change in active range of motion in elbow extension was greater for the experimental than for control subjects (33.5% vs. 18.7%). The Modified Ashworth Scale (extension) scores showed comparable changes of a mean 9.3% improvement for experimental versus 8.6% for the control subjects.
Conclusion
This study confirmed the efficacy of botulinum toxin type-A in tone management and occupational therapy in contracture reduction. It also showed the value of dynamic splinting in maintaining gains in range of motion.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cooper E. Proceedings of the Stroke Disparities Advisory Panel Meeting. November 8, 2002. Bethesda, MD: National Institute of Neurological Disorders and Stroke; 2002.
Fang J, Alderman MH. Trend of stroke hospitalization, United States, 1988–1997. Stroke. 2001;32:2221–2226.
Sun SF, Hsu CW, Hwang CW, et al. Application of combined botulinum toxin type A and modified constraint-induced movement therapy for an individual with chronic upper-extremity spasticity after stroke. Phys Ther. 2006;86:1387–1397.
Verplancke D, Snape S, Salisbury CF, Jones PW, Ward AB. A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clin Rehabil. 2005;19:117–125.
Francisco GE. Botulinum toxin for post-stroke spastic hypertonia: a review of its efficacy and application in clinical practice. Ann Acad Med Singapore. 2007;36:22–30.
Francisco GE. Botulinum toxin: dosing and dilution. Am J Phys Med Rehabil. 2004;83(suppl.):S30–S37.
Childers MK, Brashear A, Jozefczyk P, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil. 2004;85:1063–1069.
Brashear A, McAfee AL, Kuhn ER, Ambrosius WT. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil. 2004;85:705–709.
Sheean G. Botulinum toxin treatment of adult spasticity: a benefit-risk assessment. Drug Saf. 2006;29:31–48.
Ravichandran E, Gong Y, Al Saleem FH, Ancharski DM, Joshi SG, Simpson LL. An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther. 2006;318:1343–1351.
Lai JM, Jones M, Willis FB. Efficacy of dynamic splinting on plantar-flexion tone and contracture seen in CVA and TBI patients: a controlled, crossover study. Proceedings of the 16th European Congress of Physical and Rehabilitation Medicine. Turin, Italy: Edizioni Minerva Medica; 2008:106–109.
Willis B. Post-TBI gait rehabilitation. Appl Neurol. 2007;3:25–26.
Nuismer BA, Ekes AM, Holm MB. The use of lowload prolonged stretch devices in rehabilitation programs in the Pacific northwest. Am J Occup Ther. 1997;51:538–543.
Shulman DH, Shipman B, Willis FB. Treating trismus with dynamic splinting: a cohort, case series. Adv Ther. 2008;25:9–16.
Willis B, Gaspar P, Neffendorf C. Device and physical therapy to unfreeze shoulder motion. BioMechanics. 2007;14:45–49.
Willis B, John M. Dynamic splinting increases flexion for hallux rigidus (pilot study). BioMechanics. 2007;14:49–53.
John M, Willis B, Protillo A. Runner’s hallux rigidus reduction and gait analysis. J Am Podiatr Med Assoc. In press.
Preston LA, Hecht JS. Spasticity Management: Rehabilitation Strategies. Bethesda, MD: American Occupational Therapy Association; 1999.
Hsu AT, Hedman T, Chang JH, et al. Changes in abduction and rotation range of motion in response to simulated dorsal and ventral translational mobilization of the glenohumeral joint. Phys Ther. 2002;82:544–556.
Vermeulen HM, Rozing PM, Obermann WR, le Cessie S, Vliet Vlieland TP. Comparison of high-grade and low-grade mobilization techniques in the management of adhesive capsulitis of the shoulder: randomized controlled trial. Phys Ther. 2006;86:355–368.
Hsu AT, Ho L, Ho S, Hedman T. Joint position during anterior-posterior glide mobilization: its effect on glenohumeral abduction range of motion. Arch Phys Med Rehabil. 2000;81:210–214.
Harvey L, Herbert R, Crosbie J. Does stretching induce lasting increases in joint ROM? A systematic review. Physiother Res Int. 2002;7:1–13.
Denham SP. Augmenting occupational therapy treatment of upper-extremity spasticity with botulinum toxin A: a case report of progress at discharge and 2 years later. Am J Occup Ther. 2008;62:473–479.
Avela J, Kyröläinen H, Komi PV. Altered reflex sensitivity after repeated and prolonged passive muscle stretching. J Appl Physiol. 1999;86:1283–1291.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lai, J.M., Francisco, G.E. & Willis, F.B. Dynamic splinting after treatment with botulinum toxin type-A: A randomized controlled pilot study. Adv Therapy 26, 241–248 (2009). https://doi.org/10.1007/s12325-008-0139-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-008-0139-2